BRADYKININ

BKs signal via two GPCRs known as the B1 (BDKRB1) and B2 (BDKRB2) receptors. These BK receptor genes were the result of tandem duplication that predated the teleost tetraploidization while no extra copy was found in teleosts. B2 is constitutively expressed and predominant in different tissues while B1 expression is induced by inflammation. B1 expression in inflammatory tissues such as a wound area and vascular injury contributes to the inflammatory edema by its vasodilatory effect on local blood vessels. B2 is ubiquitously expressed in different tissues. In the aorta and large muscular arteries, including the carotid and mesenteric arteries, B2 is localized predominantly in the endothelium. However, in small arterioles toward the urinary bladder, myometrium, breast, etc., B2 is located predominantly in the smooth muscle rather than the endothelium. bdkrb2- overexpressed zebrafish induce IP3 accumulation by BK with an EC50 of 6.6 nM.

Both B1 and B2 trigger a typical Ca signaling of GPCRs. Receptor activation leads to phospholipase C (PLC) activation, intracellular Ca mobilization, release of endothelium-dependent relaxation factor (EDRF), and activation of PKC and cytosolic PLA2 that results in the release of prostaglandins (PGs). The endothelial nitric oxide synthase (eNOS) is also stimulated by B2 activation, leading to an increase in NO, stimulation of guanylyl cyclase, and an increase in cGMP. Most of these factors are EDRFs and are contributing to the hypotensive effect of BK. However, in smooth muscle cells, B2 activation activates PLC directly, leading to a transient increase in Ca2+ flux to induce muscle contraction. Although BK mostly induces vasorelaxation via endothelium-dependent signalings, in small arterioles where B2 is predominately localized in the smooth muscle cells, BK induces vasoconstriction. In the light of this dual function, [Arg0 ]-BK injection in teleosts was a vasopressor and could be related to a direct stimulation of B2 on smooth muscles, as the endothelium-dependent relaxing system is not prominent in teleosts.

[Lys0 , des-Arg9 ]-BK is used as a B1 receptor agonist. Cereport (RMP-7) is a selective B2 agonist, and has been shown to transiently increase the permeability of the blood-brain barrier. The B1 antagonist BI-113823 possesses an antiinflammatory function. Icatibant (HOE 140 or JE 049) is a potent, specific, and selective peptidomimetic B2 antagonist.

Amorphous solid.

Leucine Enkephalin acetate salt hydrate has been used in the calibration of the Q-Tof Micro hybrid, triple quadrupole-orthogonal acceleration time of flight (TOF) instrument in single-stage TOF mode. It has also been used to perform the calibration of mass spectrometry. It has also been used in liquid chromatography-mass spectrometry (LCMS)/MS for calibration of the system and for relative correction of the spectra.

Bradykinin is used to lower blood pressure, increase bradykinin (by inhibiting its degradation) further lowering blood pressure. Bradykinin dilates blood vessels via the release of prostacyclin, nitric oxide, and endothelium-derived hyperpolarizing factor.

ChEBI: A linear nonapeptide messenger belonging to the kinin group of proteins, with amino acid sequence RPPGFSPFR. Enzymatically produced from kallidin in the blood, it is a powerful vasodilator that causes smooth muscle contraction, and may mediate inflammation

The kallikrein–kinin system is an enzymatic pathway giving rise to two predominant vasoactive peptides, kallidin and bradykinin. Kallikrein, the enzyme responsible for the formation of these peptides, exists in plasma and tissues. However, circulating levels of the end products, kallidin and bradykinin, are quite low because the kallikrein enzymes are present largely in inactive forms. In addition, the short half-life of these peptides (15 seconds) also contributes to low plasma levels. In general, the kinins produce relaxation of vascular smooth muscle and vasodilation. Bradykinin causes vascular smooth muscle relaxation by stimulating the endothelium to release prostacyclin and nitric oxide. Blood flow to the brain, heart, viscera, skeletal muscle, and glands is increased. In nonvascular smooth muscle, bradykinin will produce a contractile response.
Other actions of kinins include activation of clotting factors simultaneously with the production of bradykinin. In the kidney, bradykinin production results in an increase in renal papillary blood flow, with a secondary inhibition of sodium reabsorption in the distal tubule. In the peripheral nervous system, bradykinin is important for the initiation of pain signals. It is also associated with the edema, erythema, and fever of inflammation.
Bradykinin exerts its physiological effects via two receptors, the B1 and B2 receptors, with most of its physiological effects being mediated by the B2 receptor. The precise function of the B1 receptor is unclear; however, some of the chronic inflammatory responses to bradykinin may be mediated through actions at this receptor.
Bradykinin antagonists of the B2 receptor are currently in development and may find utility in the treatment of pain associated with burns and such chronic inflammatory disorders as arthritis, asthma, and chronic pain.

Induces the release of nitric oxide. Other physiological functions include stimulation of pain receptors, inhibition of cAMP accumulation, induction of smooth muscle contraction, and vasodilation. Also involved in edema resulting from trauma or injury. Improves post-ischemic recovery of heart via a nitric oxide-dependent mechanism.

Powerful vasodilator; increased capillary permeability; stimulates pain receptors; contraction of smooth muscle; teratogen; mutagenic.

Product does not compete with ATP.

9-peptide, produced in response to tissue damage, inflammation, viral infections, etc. Produces pain, increased vascular permeability, and synthesis of prostaglandins.

-20°C